Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 10/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | NAAA | Q02083 | 3/20 | 0.41 |
| ▸ | MIF | P14174 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6014469 | 0.98 | SIGMAR1 (0.50) | SIGMAR1L3MBTL1MAOA | |
| SCHEMBL6014578 | 0.85 | MAPT (0.44) | SIGMAR1MAOAMAPT | |
| SCHEMBL6014448 | 0.77 | SIGMAR1 (0.46) | SIGMAR1L3MBTL1 | |
| SCHEMBL4560416 | 0.74 | IDO1 (0.52) | MAOAMAPT | |
| SCHEMBL28811665 | 0.74 | SIGMAR1 (0.48) | SIGMAR1MAOANAAAMIFMAPT | |
| SCHEMBL10895799 | 0.74 | SIGMAR1 (0.48) | SIGMAR1MAOANAAAMIFMAPT | |
| SCHEMBL6014561 | 0.74 | MAOA (0.52) | SIGMAR1MAOANAAAMIFMAPT | |
| SCHEMBL6014606 | 0.74 | MAOA (0.52) | SIGMAR1MAOANAAAMIFMAPT | |
| SCHEMBL10894556 | 0.73 | SIGMAR1 (0.47) | SIGMAR1MAOANAAAMIFMAPT | |
| SCHEMBL6014547 | 0.73 | L3MBTL1 (0.50) | SIGMAR1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7078406-B2 | Substituted diphenyloxazoles, the synthesis thereof, and the use thereof as fluorescence probes | JOHNSON & JOHNSON PHARMACEUTICAL RESEARCH & DEVELOPMENT, L.L.C. (US) | 2006-07-18 | — | — | US | disclosed |
| US-20040248851-A1 | Substituted diphenyloxazoles, the synthesis thereof, and the use thereof as fluorescence probes | Life Technologies Corporation | 2004-12-09 | — | — | US | disclosed |
| US-6815445-B2 | FOR USE AS FLUORESCENCE DYES AND PROBES | Life Technologies Corporation | 2004-11-09 | — | — | US | disclosed |
| EP-1442027-A1 | SUBSTITUTED DIPHENYLOXAZOLES, THE SYNTHESIS THEREOF, AND THE USE THEREOF AS FLUORESCENCE PROBES | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2004-08-04 | — | — | EP | disclosed |
| US-20030105111-A1 | Substituted diphenyloxazoles, the synthesis thereof, and the use thereof as fluorescence probes | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2003-06-05 | — | — | US | disclosed |
| WO-2003031419-A1 | SUBSTITUTED DIPHENYLOXAZOLES, THE SYNTHESIS THEREOF, AND THE USE THEREOF AS FLUORESCENCE PROBES | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2003-04-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040248851-A1 | Substituted diphenyloxazoles, the synthesis thereof, and the use thereof as fluorescence probes | DHFR, FPR1, CYP1A1 | SIGMAR1 1287/4885L3MBTL1 2205/4885MAOA 297/4885 |
| US-20030105111-A1 | Substituted diphenyloxazoles, the synthesis thereof, and the use thereof as fluorescence probes | DHFR, FPR1, CYP1A1 | SIGMAR1 1287/4885L3MBTL1 2205/4885MAOA 297/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.